|
業務類別
|
Drug Manufacturers - General |
|
業務概覽
|
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis). |
| 公司地址
| 225 Binney Street, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 679-2000 |
| 傳真號碼
| +1 302 636-5454 |
| 公司網頁
| https://www.biogen.com |
| 員工數量
| 7500 |
| Ms. Susan H. Alexander |
Executive Vice President and Chief Legal Officer |
美元 1.03M |
11/03/2026 |
| Dr. Jane Grogan, PhD |
Executive Vice President, Head of Research |
-- |
06/02/2026 |
| Dr. Ginger Gregory, PhD |
Executive Vice President and Chief Human Resources Officer |
-- |
06/02/2026 |
| Ms. Robin C. Kramer |
Executive Vice President and Chief Financial Officer |
美元 759.62K |
06/02/2026 |
| Mr. Sean Godbout |
Vice President, Chief Accounting Officer and Global Corporate Controller |
-- |
06/02/2026 |
| Mr. Adam Keeney, PhD |
Executive Vice President and Head of Corporate Development |
-- |
06/02/2026 |
| Dr. Priya A. Singhal, M.D. |
Executive Vice President and Head of Development |
美元 929.71K |
06/02/2026 |
| Mr. Rachid Izzar |
Executive Vice President, Global Product Strategy and Commercialization |
-- |
06/02/2026 |
| Mr. Christopher A. Viehbacher |
Director, President and Chief Executive Officer |
美元 1.73M |
28/04/2026 |
| Ms. Nicole C. Murphy |
Executive Vice President, Pharmaceutical Operations and Technology |
美元 909.11K |
06/02/2026 |
|
|
| Ms. Susan K. Langer |
Independent Director |
28/04/2026 |
| Ms. Caroline D. Dorsa |
Chairman of the Board |
11/02/2026 |
| Dr. Eric K. Rowinsky,M.D. |
Independent Director |
28/04/2026 |
| Mr. William A. Hawkins, III |
Independent Director |
28/04/2026 |
| Dr. Stephen A. Sherwin, M.D. |
Independent Director |
28/04/2026 |
| Professor Menelas Pangalos, PhD |
Independent Director |
28/04/2026 |
| Dr. Lloyd B. Minor, M.D. |
Independent Director |
28/04/2026 |
| Dr. Maria C. Freire, PhD |
Independent Director |
11/02/2026 |
| Mr. Jesus B. Mantas |
Independent Director |
28/04/2026 |
| Mr. Monish D. Patolawala |
Independent Director |
28/04/2026 |
| Mr. Christopher A. Viehbacher |
Director, President and Chief Executive Officer |
28/04/2026 |
|
|
|
|
